Read by QxMD icon Read


K F Mose, M Burton, M Thomassen, F Andersen, T A Kruse, Q Tan, L Skov, M A Røpke, T Litman, O Clemmensen, B W Kristensen, P S Friedmann, K E Andersen
The gene expression time-course of repeated challenge of contact allergy (CA) remains largely unknown. Therefore, using diphenylcyclopropenone (DPCP) as model allergen in healthy humans we set out to examine: i) the monotonous and complex gene expression time-course trajectories following repeated challenges with DPCP to find the predominant gene expression pattern, ii) the time-course of cell infiltration following repeated DPCP challenges, and iii) the transcriptome of a repeated CA exposure model. We obtained punch biopsies from control and DPCP exposed skin from ten DPCP sensitized individuals at 5-6 monthly elicitation challenges...
March 31, 2017: Experimental Dermatology
S J Choe, B J Kim, J Choi, W S Lee
Contact immunotherapy using diphenylcyclopropenone (DPCP) is commonly used treatment modality for moderate to severe alopecia areata (AA)(1) . The most common side effects associated with topical immunotherapy using DPCP include eczema, hyperpigmentation, hypopigmentation, vitiligo, and cicatricial alopecia. However, we identified an interesting case of a patient whose entire scalp of straight hair (Figure 1A) became curly after DPCP immunotherapy, which has not been reported previously. A 24-year-old male patient with no specific medical or dermatological history reported to our dermatology outpatient clinic because of sudden hair loss and started treatment after being diagnosed with AA...
February 13, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
Carrie Yeung, Teresa M Petrella, Frances C Wright, Wadid Abadir, Nicole J Look Hong
BACKGROUND: Diphencycprone (DPCP) is an immune contact sensitizer applied to melanoma lesions. Early studies show favorable efficacy. We present the first North-American series of patients treated with DPCP. METHODS: A single center retrospective study of patients with in-transit or unresectable melanoma lesions treated with DPCP from December 1,2014 to December 31,2015 was completed. Primary objectives were response rate and toxicity. Secondary objective was health-related quality of life assessment with the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire...
February 6, 2017: Expert Review of Clinical Immunology
Sung Jay Choe, Won-Soo Lee
BACKGROUND: Few treatment modalities are available for treating alopecia areata (AA) of the eyebrow. Due to the anatomical proximity of the eyebrows to the eyes, safety issues and side effects should always be taken into consideration when choosing the treatment modality. This study was designed to examine the efficacy of superficial cryotherapy on patients with AA of the eyebrow. METHODS: Superficial cryotherapy was performed every other week on the right eyebrow (SC-treated) in a total of 20 patients who had been previously treated with diphenylcyclopropenone (DPCP) immunotherapy on the scalp...
February 2017: International Journal of Dermatology
Nicholas Gulati, Richard D Carvajal, Michael A Postow, Jedd D Wolchok, James G Krueger
No abstract text is available yet for this article.
July 2016: Experimental Dermatology
Zekayi Kutlubay, Burhan Engin, Abdullah Songur, Server Serdaroglu, Yalcin Tuzun
Topical immunotherapy made by diphenylcyclopropenone (DPCP) is an alternative treatment that can be used safely and efficaciously in recalcitrant alopecia areata patients. DPCP-induced vitiligo is a rare, but documented, unwanted side effect. The real mechanism of DPCP-induced vitiligo is not well known.
August 2016: Journal of Cosmetic and Laser Therapy: Official Publication of the European Society for Laser Dermatology
Ivana Kosarac, Cariton Kubwabo, Warren G Foster
Over the last few years, the use of organophosphate flame retardants (OPFRs) has been on the rise; however, there are knowledge gaps in both the human health effects of OPFRs and levels of human exposure. Currently, human biomonitoring data on the levels of OPFR metabolites in the Canadian population are still non-existent. Herein we describe a novel method to measure nine urinary OPFR metabolites using solid phase extraction and ultra performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS)...
March 1, 2016: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Hyung Kwon Park, Joung Soo Kim
Diphenylcyclopropenone (DPCP) immunotherapy has been shown to be efficacious for the treatment of warts, especially periungual warts for which destructive techniques are limited. However, factors affecting the duration of treatment of periungual warts have not been studied. A total of 61 patients with periungual warts who were completely cured with DPCP immunotherapy were included in this study. Age, sex, disease duration, location (fingernail, toenail, or both), number of warts, diameter of the largest wart, application number for sensitization and two types of sensitization reactions, erythema and blister index (EBI), and pruritus index were evaluated...
March 2016: Dermatologic Therapy
Katherine S Chiang, Natasha A Mesinkovska, Melissa P Piliang, Wilma F Bergfeld
Diphenylcyclopropenone (DPCP) is widely considered the most effective topical immunotherapy for refractory or extensive alopecia areata (AA), but questions regarding how long to try DPCP therapy before terminating and what factors are prognostic of therapeutic success still remain unanswered. In this retrospective study of 50 AA patients, we evaluated DPCP efficacy and identified patient factors predictive of therapeutic success/failure. The median duration of DPCP treatment was 3 years, with 47% patients experiencing their first regrowth in the first 6 months of DPCP therapy, 20% between 6 months-1 year, and 8% between 1-2 years...
November 2015: Journal of Investigative Dermatology. Symposium Proceedings
Karen G Bulock, James P Cardia, Pamela A Pavco, William R Levis
Diphencyprone (DPCP) is a potent topical sensitizing agent that has been used since the late 1970s by physicians for the treatment of alopecia areata (AA), viral warts (human papillomavirus) and cutaneous metastases of melanoma. Although to date the compound is not approved as a drug by the FDA or EMA, physicians have continued to use DPCP because of its proven effects in these dermatological conditions. The use of the drug has been highly variable because of differences in compounding, and as a result, the literature reports vary widely in the concentrations used for sensitization and challenge treatment with DPCP...
November 2015: Journal of Investigative Dermatology. Symposium Proceedings
Robert Doherty
As physicians seek innovative practice models, one that is gaining ground is for practices to contract with patients to pay directly for some or all services-often called cash-only, retainer, boutique, concierge, or direct primary care or specialty care practices. Such descriptions do not reflect the variability found in practices. For the purposes of this paper, the American College of Physicians (ACP) defines a direct patient contracting practice (DPCP) as any practice that directly contracts with patients to pay out-of-pocket for some or all of the services provided by the practice, in lieu of or in addition to traditional insurance arrangements, and/or charges an administrative fee to patients, sometimes called a retainer or concierge fee, often in return for a promise of more personalized and accessible care...
December 15, 2015: Annals of Internal Medicine
R A Kuin, P I Spuls, J Limpens, E J van Zuuren
AIM: To assess the efficacy and safety of topical diphenylcyclopropenone (DPCP) in patients with alopecia areata. SETTING AND DESIGN: Study selection, data extraction, risk of bias assessment and analyses were carried out independently by two authors. The quality of evidence was rated with Grading of Recommendations Assessment, Development and Evaluation (GRADE). No randomised trials were identified, but 11 case series, conducted in dermatology departments in the Netherlands, UK, Iran, Italy, Egypt and Greece were included...
October 2015: British Journal of Dermatology
Nicholas Gulati, Mayte Suárez-Fariñas, Joel Correa da Rosa, James G Krueger
Diphencyprone (DPCP) is a hapten that causes delayed-type hypersensitivity (DTH) reactions in human skin, and is used as a topical therapeutic for alopecia areata, warts, and cutaneous melanoma metastases.  We examined peak DTH reactions induced by DPCP (3 days post-challenge) by comprehensive gene expression and histological analysis.  To better understand how these DTH reactions naturally resolve, we compared our DPCP biopsies to those from patients with psoriasis vulgaris, a chronic inflammatory disease that does not resolve...
2015: F1000Research
Nicholas Gulati, Marianne B Løvendorf, John R Zibert, Kemal M Akat, Neil Renwick, Thomas Tuschl, James G Krueger
Diphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions. MicroRNAs (miRNAs) are short non-coding RNAs that negatively regulate gene expression and have been implicated in various inflammatory skin diseases, but their role in DTH reactions is not well understood. We generated global miRNA expression profiles (using next-generation sequencing) of DPCP reactions in skin of seven healthy volunteers at 3, 14 and 120 days after challenge. Compared to placebo-treated sites, DPCP-challenged skin at 3 days (peak inflammation) had 127 miRNAs significantly deregulated...
December 2015: Experimental Dermatology
Glen Davison, Corinna Kehaya, Bethany C Diment, Neil P Walsh
BACKGROUND: Carbohydrate (CHO) supplementation during prolonged exercise is widely acknowledged to blunt in vitro immunoendocrine responses, but no study has investigated in vivo immunity. PURPOSE: To determine the effect of CHO supplementation during prolonged exercise on in vivo immune induction using experimental contact hypersensitivity with the novel antigen diphenylcyclopropenone (DPCP). METHODS: In a double-blind design, 32 subjects were randomly assigned to 120 min of treadmill exercise at 60 % [Formula: see text] with CHO (Ex-CHO) or placebo (Ex-PLA) supplementation...
June 2016: European Journal of Nutrition
Y Kimura, Y Kida, Y Matsushita, Y Yasaka, M Ueno, K Takahashi
Translational diffusion coefficients of diphenylcyclopropenone (DPCP), diphenylacetylene (DPA), and carbon monoxide (CO) in 1-butyl-3-methylimidazolium bis(trifluoromethanesulfonyl)imide ([BMIm][NTf2]) and 1-ethyl-3-methylimidazolium bis(trifluoromethanesulfonyl)imide ([EMIm][NTf2]) were determined by the transient grating (TG) spectroscopy under pressure from 0.1 to 200 MPa at 298 K and from 298 to 373 K under 0.1 MPa. Diffusion coefficients of these molecules at high temperatures in tributylmethylphosphonium bis(trifluoromethanesulfonyl)imide ([P4441][NTf2]), and tetraoctylphosphonium bis(trifluoromethanesulfonyl)imide ([P8888][NTf2]), and also in the mixtures of [BMIm][NTf2], N-methyl-N-propylpiperidinium bis(trifluoromethanesulfonyl)imide ([Pp13][NTf2]), and trihexyltetradecylphosphonium bis(trifluoromethanesulfonyl)imide ([P66614][NTf2]) with ethanol or chloroform have been determined...
June 25, 2015: Journal of Physical Chemistry. B
Giulia Ganzetti, Oriana Simonetti, Anna Campanati, Katia Giuliodori, Vitangelo Scocco, Marina Brugia, Massimo Tocchini, Anamaria Offidani
Osteopontin (OPN) is a multifunctional glycophosphoprotein secreted by many cell types, including osteoblasts, lymphocites, macrophages, epithelial cells, and vascular smooth muscle cells. It has been implicated in many physiological and pathological processes, such as cell-mediated immunity, inflammation, cell survival, and tumor invasion and metastasis. Osteopontin has multiple emerging roles in cutaneous biology and pathology and OPN involvement has been emphasized in Th1-mediated diseases such as psoriasis...
2015: Acta Dermatovenerologica Croatica: ADC
Murat Durdu, Deren Özcan, Mete Baba, Deniz Seçkin
BACKGROUND: Some patients with chronic extensive alopecia areata (AA) may be refractory to topical immunotherapy. Combination therapy is recommended for such patients. Efficacy and safety of a combination therapy with diphenylcyclopropenone (DPCP) and anthralin in chronic extensive AA is unknown. OBJECTIVE: We sought to determine whether the combination therapy of DPCP and anthralin is superior to DPCP alone in chronic extensive AA. METHODS: We retrospectively analyzed the efficacy, side effects, and relapse rates of DPCP (alone or with anthralin) in chronic extensive AA...
April 2015: Journal of the American Academy of Dermatology
Dong-Woo Suh, Bark-Lynn Lew, Woo-Young Sim
BACKGROUND: Diphenylcyclopropenone (DPCP) immunotherapy has been used to treat warts, particularly in patients, such as children, who cannot endure treatment-related pain and in patients with large numbers of warts. However, the efficacy of DPCP immunotherapy remains subject to much controversy. Specifically, cure rates and treatment durations have varied across reports, primarily because of the lack of large-scale studies. METHODS: We performed an uncontrolled, open-label study to investigate the efficacy of DPCP immunotherapy for the treatment of cutaneous warts...
December 2014: International Journal of Dermatology
Bethany C Diment, Matthew B Fortes, Jason P Edwards, Helen G Hanstock, Mark D Ward, Huw M Dunstall, Peter S Friedmann, Neil P Walsh
PURPOSE: To examine the effects of intensity and duration of exercise stress on induction of in vivo immunity in humans using experimental contact hypersensitivity (CHS) with the novel antigen diphenylcyclopropenone (DPCP). METHODS: Sixty-four healthy males completed either 30 min running at 60% V˙O2peak (30MI), 30 min running at 80% V˙O2peak (30HI), 120 min running at 60% V˙O2peak (120MI), or seated rest (CON). Twenty min later, the subjects received a sensitizing dose of DPCP; and 4 wk later, the strength of immune reactivity was quantified by measuring the cutaneous responses to a low dose-series challenge with DPCP on the upper inner arm...
July 2015: Medicine and Science in Sports and Exercise
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"